Category: Clinical Trials

Teitur Trophics has announced successful completion of a Phase I clinical trial for TT-P34, described as a first-in-class peptide therapy targeting Parkinson’s disease. The announcement represents an encouraging milestone for a novel approach to addressing one of the most challenging neurodegenerative conditions affecting millions of people worldwide.

Phase I trials are primarily designed to evaluate the safety and tolerability of a new therapeutic candidate in humans, and successful results at this stage are a critical first step before any treatment can advance toward larger studies. The fact that TT-P34 has cleared this initial hurdle suggests the peptide was well-tolerated among trial participants, paving the way for further investigation into its potential effectiveness against Parkinson’s disease symptoms and progression.

Parkinson’s disease remains an area of significant unmet medical need, with current treatments largely focused on managing symptoms rather than addressing underlying disease mechanisms. The emergence of a peptide-based candidate specifically designed to target this condition reflects the growing interest in peptide therapeutics as a versatile and precise tool in neurology. Peptides offer researchers the ability to design molecules that can interact with specific biological pathways implicated in neurodegeneration, potentially opening doors to treatments that go beyond symptom management.

While much work remains before TT-P34 could become an approved therapy, this successful Phase I outcome is a meaningful signal for patients, families, and the broader research community following developments in Parkinson’s disease treatment. Continued clinical development, including future Phase II and Phase III trials, will be needed to further establish the peptide’s safety profile and determine its therapeutic potential in larger and more diverse patient populations.

The peptide research community will likely watch closely as Teitur Trophics moves forward with next steps in the development pipeline. Innovations like TT-P34 highlight the expanding role peptides are playing across various therapeutic areas, including neurology, and underscore the ongoing effort to bring new options to patients facing serious and complex conditions.

This article is for informational purposes only and is not medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Teitur Trophics announces successful results from Phase I clinical trial of first-in-class Parkinson’s disease peptide TT-P34 – The Manila Times

A new clinical trial is underway to explore how TAK-664, a subcutaneous immunoglobulin (IgG) replacement therapy already approved worldwide, can help patients with primary immunodeficiency diseases (PIDD) who have never before received IgG treatment. This is an important step forward for a therapy that has already helped many patients manage their conditions, as researchers now turn their attention to those just beginning treatment.

PIDD affects the immune system’s ability to produce enough antibodies, particularly IgG, which plays a critical role in protecting the body from infections. For people newly diagnosed and starting therapy, getting IgG levels to a healthy target—and keeping them there—can be a crucial turning point in managing their health and reducing infection risk.

This study aims to determine whether an initial dosing schedule—daily doses for five days followed by an additional dose on day eight—can effectively raise IgG levels to target ranges for these treatment-naïve patients. Researchers will also examine whether a simpler once-weekly maintenance schedule can help sustain those IgG levels over time. This kind of research is valuable because it could help clarify optimal dosing strategies for people just starting on IgG replacement therapy, potentially making the transition into treatment smoother and more predictable.

In addition to tracking IgG levels, the study will monitor how many infections participants experience and how those infections are treated during the trial. This real-world outcome data is meaningful because it helps connect laboratory measurements of antibody levels to actual health outcomes that matter most to patients—fewer infections and better quality of life.

Because TAK-664 is already approved for subcutaneous IgG replacement therapy in various markets, this study represents a continued effort to refine and optimize how the treatment can best serve new patient populations, including those who have not yet had the benefit of any IgG therapy. Expanding research into different patient groups and dosing schedules reflects an encouraging commitment to improving accessibility and effectiveness of care for people living with immune deficiencies.

As with all clinical research, results will need to be evaluated over time, and this trial is still in progress. Patients and caregivers interested in learning more can find additional details through the official clinical trial registry. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Study of TAK-664 in People With Primary Immunodeficiency Diseases Who Have Not Yet Been Treated With Immunoglobulins

A promising new clinical trial is set to investigate whether combining bexmarilimab with the established immunotherapy drug nivolumab could offer new hope for patients whose cancers have developed resistance to standard PD-1 immunotherapy treatments. The Phase I/II trial will focus specifically on two challenging cancer types: non-small cell lung cancer (NSCLC) and melanoma.

What makes this research particularly encouraging is the underlying science. Early studies suggest that bexmarilimab may work by changing the behavior of certain immune cells within tumors, essentially helping them generate a stronger “attack signal.” This could make it easier for other immune cells to recognize and target cancer cells more effectively. For patients whose cancers have stopped responding to PD-1 inhibitors like nivolumab, this mechanism offers a potential pathway to restore the immune system’s ability to fight back against tumors that have learned to evade detection.

The trial is structured thoughtfully in two phases. Phase I will carefully escalate doses of bexmarilimab alongside a fixed dose of nivolumab in patients with various solid tumors, allowing researchers to identify the safest and most effective dose combination. This methodical approach ensures patient safety remains a priority while researchers gather crucial data. Phase II will then apply the optimized dose to two specific patient groups—those with NSCLC and those with melanoma—to evaluate how well the combination performs in these particular cancer types.

This research represents an important avenue of investigation for the growing challenge of immunotherapy resistance. As PD-1 inhibitors like nivolumab have become standard treatments for many cancers, a subset of patients inevitably develop resistance over time, leaving fewer options for continued treatment. If successful, this combination approach could potentially extend the effectiveness of immunotherapy for patients who might otherwise have limited choices remaining.

The peptide and immunotherapy research community continues to explore innovative combination strategies to overcome treatment resistance, and trials like this one contribute valuable knowledge to that broader effort. As this study progresses through its phases, it will help clarify both the safety profile and potential effectiveness of this novel combination, offering a data-driven path forward for one of oncology’s persistent challenges.

This article is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider regarding any treatment decisions.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC

A new randomized, double-blind, placebo-controlled clinical trial has begun to evaluate efruxifermin (EFX), an investigational therapy being studied for patients with compensated cirrhosis resulting from NASH (non-alcoholic steatohepatitis) or MASH (metabolic dysfunction-associated steatohepatitis). The study, registered on ClinicalTrials.gov, represents an important step forward in the search for effective treatments for advanced liver disease.

Efruxifermin is part of a class of engineered protein and peptide-based therapies designed to mimic the body’s natural fibroblast growth factor 21 (FGF21), a hormone involved in regulating metabolism and supporting liver health. Researchers have been exploring FGF21-based approaches because of their potential to influence how the liver processes fat and manages inflammation, both of which play a role in the progression of fatty liver disease to more serious conditions like cirrhosis.

What makes this trial particularly encouraging is its focus on patients who already have compensated cirrhosis, a more advanced stage of liver scarring where treatment options remain limited. By specifically studying this patient population across multiple medical centers, researchers aim to gather meaningful data on how EFX may help support liver function and potentially slow or improve disease progression in people who need new options the most.

The use of a randomized, double-blind, placebo-controlled design reflects a rigorous scientific approach, helping ensure that any observed effects can be reliably attributed to the treatment itself rather than other factors. This type of methodology is considered a gold standard in clinical research and lends credibility to the eventual findings, whatever they may show.

For the broader peptide and metabolic health research community, this trial adds to a growing body of work exploring how engineered proteins and peptide therapies might address complex conditions like NASH and MASH, which affect millions of people worldwide and currently have few approved treatment options. As this study progresses, it will contribute valuable knowledge to help guide future research and, potentially, new treatment approaches for those affected by advanced liver disease.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

A newly registered clinical trial on ClinicalTrials.gov signals encouraging news for patients who have been responding well to opnurasib, also known as JDQ443, an investigational KRAS G12C-targeted therapy being developed by Novartis. The study, a ‘rollover’ trial, is specifically designed to allow participants who are already experiencing benefit from opnurasib—whether used alone or in combination with other treatments—to continue receiving it beyond the scope of their original studies.

Rollover studies like this one are an important and reassuring part of the clinical research process. When patients in earlier-phase trials show meaningful benefit from an investigational treatment, researchers and sponsors often design follow-on protocols to ensure that access to the therapy isn’t interrupted simply because the initial study has concluded. This approach reflects a growing recognition in the research community that continuity of care matters, particularly for patients who may not have many other effective options.

Opnurasib belongs to a class of targeted therapies designed to inhibit KRAS G12C, a specific genetic mutation found in certain cancers. Peptide and small-molecule approaches targeting this mutation have generated significant interest in oncology research in recent years, as they represent a more precise way to address tumors driven by this particular genetic alteration. The fact that Novartis is investing in a dedicated rollover mechanism suggests that data from prior opnurasib studies have been promising enough to warrant continued investigation and patient access.

Beyond simply extending access, this rollover study will continue to monitor participant safety over time, contributing valuable long-term data to the broader understanding of opnurasib’s benefit-risk profile. This kind of extended observation is valuable for the entire research community, helping to build a more complete picture of how sustained treatment with targeted peptide-based therapies performs in real-world, longer-term use.

For patients and families following developments in targeted cancer therapies, news like this offers a hopeful signal: when a treatment is working, mechanisms exist to help ensure that progress isn’t lost. As opnurasib continues through clinical evaluation, this rollover study represents a thoughtful, patient-centered step in its development pathway. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

A newly launched multicenter Phase 1-1b clinical trial is set to evaluate an innovative peptide-based approach to treating solid tumors that express the Gastrin-Releasing Peptide Receptor (GRPR). The study will investigate two radiolabeled peptide compounds, [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642, alongside companion imaging agents [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631, in patients with locally advanced, unresectable, or metastatic disease.

This research reflects a growing and exciting trend in oncology known as theranostics, where peptides are engineered to both find and treat cancer. By targeting GRPR, a receptor commonly overexpressed on certain tumor cells, these peptide constructs are designed to deliver radioactive isotopes directly to cancerous tissue while sparing healthy cells. The imaging component allows physicians to first visualize whether a patient’s tumor expresses the target receptor, potentially enabling more personalized treatment decisions before therapy even begins.

The trial’s primary goals include assessing safety, dosimetry, and preliminary efficacy signals, foundational steps that are essential before any peptide therapy can advance toward wider use. Peptide-receptor radionuclide therapies have already shown meaningful benefit in other cancer types, such as neuroendocrine tumors, so extending this targeted strategy to GRPR-expressing solid tumors represents a promising area of exploration for patients who may have limited treatment options.

What makes this approach particularly encouraging is its dual-purpose design: the same peptide scaffold can be adapted for both diagnostic imaging and therapeutic delivery. This kind of precision medicine strategy underscores how far peptide science has advanced, moving beyond simple hormone analogs toward sophisticated molecular delivery systems capable of carrying therapeutic payloads exactly where they’re needed.

While it will take time for results from this early-phase study to emerge, its initiation marks a meaningful step forward in expanding the toolkit of peptide-based cancer therapies. As research progresses, studies like this one help pave the way for more targeted, potentially better-tolerated treatment options in oncology.

This article is for informational purposes only and is not medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors

Researchers have launched a new clinical trial to evaluate a combination therapy approach for patients battling metastatic soft tissue sarcoma (mSTS), a challenging group of cancers that includes myxofibrosarcoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, cutaneous angiosarcoma, and undifferentiated sarcoma. The study, registered on ClinicalTrials.gov, will investigate whether pairing the targeted therapy zanzalintinib with the established immunotherapy agents ipilimumab and nivolumab can offer a well-tolerated and effective treatment strategy for these difficult-to-treat cancers.

Soft tissue sarcomas represent a diverse and often treatment-resistant category of cancers, making the search for new therapeutic combinations especially important. By combining a targeted agent with two immune checkpoint inhibitors that are already used in various cancer treatments, investigators hope to harness multiple mechanisms of action simultaneously — potentially improving outcomes for patients who currently have limited options.

This trial reflects a broader trend in oncology research toward combination therapies that pair targeted treatments with immunotherapy. The rationale behind this approach is that while ipilimumab and nivolumab work to boost the immune system’s ability to recognize and attack cancer cells, zanzalintinib may help by targeting specific pathways involved in tumor growth and blood vessel formation, potentially creating a more favorable environment for the immune therapies to work effectively.

While this trial is still in its early stages and results have not yet been reported, the initiation of this study represents a meaningful step forward for the sarcoma research community. Metastatic soft tissue sarcomas have historically been difficult to treat, and any new avenue of investigation offers hope for patients and families affected by these rare cancers. The scientific community will be watching closely as this trial progresses to see whether this combination approach can improve tolerability and efficacy compared to existing treatment options.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma